

MEDICAL AFFAIRS

# SIRT and CS-PHP for Metastasized Uveal Melanoma

A Retrospective Comparative Study

## Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study

| LEAD AUTHOR |

Dr. Manuel Kolb

Interventional Radiologist (Uni Tübingen)

**TYPE OF STUDY:** Retrospective, comparative, single institution

**AIM:** Compare the outcome of patients treated with either SIRT or CS-PHP

**DATES OF PERIOD:** December 2013 – February 2020, follow up period ended 21 September 2021


**YEAR:** 2023

**COHORT:** 62 mUM (n = 34 with SIRT, receiving 41 cycles; n = 28 with CS-PHP, receiving 56 cycles)

SOURCE: <https://www.mdpi.com/2072-6694/15/20/4942>

# Flow Chart of Patient Selection

Kolb et al.



# Patient Selection and Baseline Characteristics


Kolb et al.

Patient Characteristics including treatments			
		SIRT	CS-PHP
Number of patients		34	28
Age in years (mean $\pm$ SD)		71 $\pm$ 10	63 $\pm$ 13
Female sex		15 (44%)	18 (64%)
Pre-treatment	Liver-targeted	6 (18%)	6 (21%)
	systemic total	10 (29%)	10 (36%)
	chemotherapy	4 (12%)	1 (4%)
	immunotherapy	6 (18%)	9 (32%)
Extrahepatic metastasis at baseline		14 (41%)	19 (68%)
Hepatic load	0-25%	26 (76%)	16 (57%)
	26-50%	8 (24%)	8 (29%)
	>50%	0	4 (14%)
Total number of cycles of SIRT/CS-PHP		39	56
Post-treatment	Systemic total	16 (47%)	20 (71%)
	chemotherapy	2 (6%)	5 (19%)
	immunotherapy	14 (41%)	17 (61%)
	other systemic	0	2 (7%)

# Response: Disease Control Rate (DCR)

Kolb et al.

By standardized evaluation of tumor response according to the RECIST 1.1, a disease control rate (DCR):




# Results: Overall Survival (OS)

Kolb et al.

## Descriptive Survival by Treatment

Kaplan-Meier graph of overall survival in days (moderated estimation).



- Significant difference in OS
- SIRT: 9,90 months vs CS-PHP: 16,96 months
- HR = 0,46, CI 95% = (0,23; 0,93), p = 0,030

# Results: Overall Survival (OS)

Kolb et al.

Overall Survival of the Study Population from the Timepoint of Study				
OS in Days	Estimation		SIRT	CS-PHP
From treatment	Moderate	mean $\pm$ SD	409.94 $\pm$ 406.96	628.71 $\pm$ 512.90
		median (range)	300.5 (19-1912)	516 (5-1836)

# Results: PFS

Kolb et al.

- Cox regression model of the moderate calculations
- No significant difference between SIRT and CS-PHP
- HR= 0,59, CI 95%: (0,34; 1,02), p = 0,057

Progression-free Survival from the Timepoint of Study Treatment				
PFS in Days	Estimation		SIRT	CS-PHP
From treatment	Moderate	mean $\pm$ SD	303.88 $\pm$ 392.28	527.71 $\pm$ 473.43
		median (range)	127.5 (19-1912)	408.5 (3-1809)

# Conclusion

Kolb et al.



Data have to be interpreted within its setting of a **retrospective single-center study**



This study demonstrates a **possible small benefit of CS-PHP over SIRT** in patients with liver-dominant mUM, especially concerning overall survival



It also shows the eminent need for prospective randomized trials, particularly to find the optimal sequencing of liver-directed therapies

- Tebentafusp and immunotherapies or a combination of these therapies

Thank you

